Create Free Account

By creating account you will get access to hot stocks & personalised emails

Fisher & Paykel Healthcare Corporation Limited

Healthcare AU FPH

33.95AUD
-0.26(0.76%)

Last update at 2024-11-13T05:10:00Z

Day Range

33.3634.25
LowHigh

52 Week Range

19.4935.76
LowHigh

Fundamentals

  • Previous Close 34.21
  • Market Cap19399.82M
  • Volume280053
  • P/E Ratio166.10
  • Dividend Yield1.16%
  • EBITDA444.80M
  • Revenue TTM1742.80M
  • Revenue Per Share TTM3.00
  • Gross Profit TTM 938.40M
  • Diluted EPS TTM0.20

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax 328.00M 504.20M 718.20M 370.50M 291.20M
Minority interest - - - - -
Net income 250.30M 376.90M 524.20M 287.30M 209.20M
Selling general administrative 431.90M 393.10M 396.60M 338.00M 327.80M
Selling and marketing expenses 431.90M 393.10M 396.60M 338.00M 327.80M
Gross profit 945.90M 1013.40M 1222.60M 845.50M 717.50M
Reconciled depreciation 99.00M 96.00M 85.00M 61.00M 41.70M
Ebit 334.70M 509.10M 723.20M 374.40M 295.90M
Ebitda 433.70M 605.10M 808.20M 435.40M 337.60M
Depreciation and amortization 99.00M 96.00M 85.00M 61.00M 41.70M
Non operating income net other - - - - -
Operating income 310.80M 468.28M 654.80M 367.24M 247.60M
Other operating expenses 34.05M 76.69M 185.42M -34.56491M 824.50M
Interest expense 6.70M 4.90M 5.00M 3.90M 4.70M
Tax provision 77.70M 127.30M 194.00M 83.20M 82.00M
Interest income 2.60M 2.60M 1.50M 8.80M 1.40M
Net interest income -4.10000M -2.30000M -3.50000M -1.70000M -1.40000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 77.70M 127.30M 194.00M 83.20M 82.00M
Total revenue 1588.60M 1642.40M 1948.20M 1273.40M 1072.10M
Total operating expenses 705.20M 643.10M 618.30M 517.50M 469.90M
Cost of revenue 642.70M 629.00M 725.60M 427.90M 354.60M
Total other income expense net -7.60000M 40.20M 32.40M -16.80000M 3.30M
Discontinued operations - - - - -
Net income from continuing ops 250.30M 376.90M 524.20M 287.30M 209.20M
Net income applicable to common shares 250.30M 376.90M 524.20M 287.30M 209.20M
Preferred stock and other adjustments - - - - -
Breakdown 2024-03-31 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Type yearly yearly yearly yearly yearly
Date 2024-03-31 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Total assets 2281.70M 2204.50M 2107.00M 2075.00M 1435.00M
Intangible assets 88.40M 85.60M 86.80M 80.00M 73.90M
Earning assets - - - - -
Other current assets 45.30M 68.90M 64.70M 49.30M 4.70M
Total liab 522.60M 451.10M 427.30M 554.10M 461.20M
Total stockholder equity 1759.10M 1753.40M 1679.70M 1520.90M 973.80M
Deferred long term liab - - - - -
Other current liab 256.40M 230.90M 231.64M 340.87M 256.86M
Common stock 404.00M 303.70M 261.20M 249.10M 225.40M
Capital stock 404.00M 303.70M 261.20M 249.10M 225.40M
Retained earnings 1095.00M 1200.50M 1181.20M 1029.20M 686.30M
Other liab - 36.80M 36.10M 33.90M 81.00M
Good will - - - - -
Other assets - 196.20M 174.40M 192.90M 107.10M
Cash 82.00M 121.00M 89.90M 97.30M 67.10M
Cash and equivalents - - - - -
Total current liabilities 385.00M 289.80M 303.90M 427.50M 334.60M
Current deferred revenue - -5.40032M 1.46M 3.33M -83.76474M
Net debt 107.10M 24.80M 14.40M 21.10M 69.10M
Short term debt 96.20M 21.30M 17.00M 26.60M 92.20M
Short long term debt 78.50M 4.20M 5.30M 11.90M 80.60M
Short long term debt total 189.10M 145.80M 104.30M 118.40M 136.20M
Other stockholder equity - -1407.29444M -1335.92953M -1175.11483M -882.71234M
Property plant equipment - 1148.20M 957.80M 882.10M 735.30M
Total current assets 704.90M 774.20M 887.90M 920.00M 518.70M
Long term investments - - - - -
Net tangible assets - 1667.80M 1592.90M 1440.90M 899.90M
Short term investments - 0.47M 200.00M 280.30M 77.70M
Net receivables 257.20M 218.50M 174.40M 222.50M 222.70M
Long term debt 35.70M 79.10M 63.00M 62.80M 22.00M
Inventory 320.40M 365.80M 358.90M 270.60M 146.50M
Accounts payable 32.40M 43.00M 53.80M 56.70M 69.30M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 260.10M 249.20M 237.30M 242.60M 62.10M
Additional paid in capital - - - - -
Common stock total equity - - - 249.10M 225.40M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - -2.20000M -3.60000M
Accumulated amortization - - - - -
Non currrent assets other 55.90M 99.62M 90.81M 134.23M 18.87M
Deferred long term asset charges - - - - -
Non current assets total 1576.80M 1430.30M 1219.10M 1155.00M 916.30M
Capital lease obligations 74.90M 62.50M 36.00M 43.70M 33.60M
Long term debt total - - - 91.80M 44.00M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -11.30000M 80.30M -202.60000M 15.00M 7.50M
Change to liabilities -19.00000M -5.70000M 65.70M 46.90M 17.40M
Total cashflows from investing activities -11.30000M -89.50000M -387.30000M -155.70000M -125.70000M
Net borrowings -4.40000M -14.10000M -10.20000M -14.90000M -0.60000M
Total cash from financing activities -197.10000M -235.80000M -188.00000M -159.00000M -113.10000M
Change to operating activities - - - - -
Net income 234.17M 349.08M 481.89M 278.17M 209.20M
Change in cash 32.20M -0.80000M 49.00M 5.50M 15.10M
Begin period cash flow 84.60M 85.40M 36.40M 30.90M 15.80M
End period cash flow 116.80M 84.60M 85.40M 36.40M 30.90M
Total cash from operating activities 222.85M 300.36M 574.83M 311.18M 253.30M
Issuance of capital stock 3.00M 3.20M 3.50M 2.30M 0.30M
Depreciation 87.85M 80.30M 74.00M 54.61M 41.70M
Other cashflows from investing activities - - -202.60000M 15.00M 7.60M
Dividends paid -195.70000M -224.90000M -181.30000M -146.40000M 114.60M
Change to inventory -6.45548M -81.78215M -114.08257M -10.06933M -10.70000M
Change to account receivables -40.51047M 48.62M -4.68832M -62.73967M -11.80000M
Sale purchase of stock 137.50M 7.50M 45.30M 15.00M 40.10M
Other cashflows from financing activities -14.40000M -14.00000M -10.20000M -9.70000M 1.80M
Change to netincome -41.90000M -107.10000M 79.60M 1.40M 7.50M
Capital expenditures 211.30M 169.80M 184.70M 170.70M 133.30M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -46.96595M -33.15743M -118.77089M -72.80900M 8.30M
Stock based compensation 8.42M 7.50M 7.08M 5.91M -
Other non cash items -99.17113M -129.01760M 18.94M -21.59097M -250.90000M
Free cash flow 11.55M 130.56M 390.13M 140.48M 120.00M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FPH
Fisher & Paykel Healthcare Corporation Limited		 -0.26 0.76% 33.95 166.10 51.81 11.13 12.06 12.02 57.37
RMD
Resmed Inc DRC		 -0.55 1.44% 37.60 32.17 24.81 11.30 7.04 7.59 22.46
ANN
Ansell Ltd		 -0.41 1.27% 31.77 35.58 21.01 2.85 1.58 1.82 14.56
NAN
Nanosonics Ltd		 -0.02 0.60% 3.30 81.00 65.79 5.78 5.33 4.96 39.15
TRJ
Trajan Group Holdings Ltd		 0.03 2.65% 1.16 - 20.00 1.18 1.78 1.47 21.80

Reports Covered

Stock Research & News

View All

Profile

Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. It provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company also offers adult respiratory products, including optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, it provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. Further, the company offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.

Fisher & Paykel Healthcare Corporation Limited

15 Maurice Paykel Place, Auckland, New Zealand, 2013

Key Executives

Name Title Year Born
Mr. Lewis G. Gradon MD, CEO & Exec. Director 1961
Ms. Lyndal York Chief Financial Officer NA
Dr. Andrew Somervell VP of Products & Technology NA
Hayden Brown Investor Relations Mang. NA
Karen Knott Gen. Mang. of Corp. Communications NA
Mr. Paul N. Shearer B.Com. Sr. VP of Sales & Marketing NA
Ms. Nicola Talbot VP of HR NA
Mr. Jonathan Rhodes VP of Supply Chain, Facilities & Sustainability NA
Mr. Marcus Driller VP of Corp. & Company Sec. NA
Chris Crone Gen. Mang. of Airvo Optiflow NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.